Shares in Abivax surged on a report that Eli Lilly LLY1.27%increase; green up pointing triangle was ready to offer 15 billion euros ($17.45 billion) for the biotech startup. Stock in the French ...
Forbes contributors publish independent expert analyses and insights. Anisha Sircar is a journalist covering tech, finance and society. This voice experience is generated by AI. Learn more. This voice ...
Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug. Eli Lilly's ...
Hosted on MSN
Guggenheim reduces PT on Eli Lilly and Company (LLY) to $1,161, reiterates 'Buy' rating
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy and hold for 20 years. On January 20, 2026, Guggenheim reduced its price target on Eli Lilly and Company (NYSE:LLY) from $1,163 to ...
SAN FRANCISCO, Jan 12 (Reuters) - Nvidia (NVDA.O), opens new tab and U.S. pharma giant Eli Lilly (LLY.N), opens new tab will spend $1 billion building a new joint research lab in the San Francisco Bay ...
WASHINGTON, Jan 15 (Reuters) - Drugmakers Eli Lilly (LLY.N), opens new tab and Novo Nordisk (NOVOb.CO), opens new tab have been sued in Texas by a compounding pharmacy that alleges they are illegally ...
How Evangeline Lilly is doing now. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. In May 2025, Evangeline Lilly posted on her Substack that she ...
Eli Lilly is set to acquire Ventyx Biosciences and its pipeline of oral anti-inflammatory agents for US$1.2 billion. Ventyx has four clinical-stage candidates: two NLRP3 inhibitors, an S1P1R inhibitor ...
In an interview with Bloomberg News, Eli Lilly Chief Financial Officer Lucas Montarce said that the Indiana-based pharma giant remains on track for a potential FDA approval of its obesity pill, ...
Eli Lilly (LLY 1.51%) has behaved more like a tech stock in recent years than like a pharma stock. Tech players are known to soar in the double and triple digits when the environment and corporate ...
Eli Lilly (LLY) is downgraded to Sell due to overstretched valuation and intensifying competition in the weight-loss drug market. LLY's heavy reliance on high-margin US sales from Zepbound and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results